Sphingosine 1 phosphate receptor modulators - Pipeline Insight, 2024

This “Sphingosine 1 Phosphate Receptor Modulators - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Sphingosine 1 Phosphate Receptor Modulators pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Sphingosine 1 Phosphate Receptor Modulators Understanding

Sphingosine 1 Phosphate Receptor Modulators: Overview

Sphingolipids represent an essential class of lipids found in all eukaryotes, and strongly influence cellular signal transduction. Autoimmune diseases like asthma and multiple sclerosis (MS) are mediated by the sphingosine-1-phosphate receptor 1 (S1P1) to express a variety of symptoms and disease patterns. Inspired by its natural substrate, an array of artificial sphingolipid derivatives has been developed to target this specific G protein-coupled receptor (GPCR) in an attempt to suppress autoimmune disorders.

Function - Sphingosine-1-phosphate receptor 1 (S1P receptor 1 or S1P1) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

Sphingosine 1 Phosphate Receptor Modulators - Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor’s function and sequester lymphocytes in lymph nodes.

Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs Chapters

This segment of the Sphingosine 1 Phosphate Receptor Modulators report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Sphingosine 1 Phosphate Receptor Modulators Emerging Drugs

Cenerimod: Idorsia Pharmaceuticals Cenerimod is a selective sphingosine-1-phosphate 1 (S1P1) receptor modulator, which potentially offers a novel approach for SLE - a disease with limited treatment options. Idorsia is investigating cenerimod, an oral once-daily tablet in patients with SLE. The drug is currently in phase 2 of clinical trials for the treatment of Systemic lupus erythematosus.

Sonepcizumab: Lpath Lpath is developing sonepcizumab, a first-in-class monoclonal antibody targeting sphingosine-1-phosphate (S1P) for the treatment of cancer as well as various. The drug is in phase 2 of clinical trials for the treatment of Wet age-related maculardegeneration
Etrasimod: Arena Pharmaceuticals Etrasimod is a next-generation, once-daily, oral, highly selective sphingosine 1-phosphate (S1P) receptor modulator discovered by Arena, and designed for optimized pharmacology and engagement of S1P receptor 1, 4 and 5 which may lead to an improved efficacy and safety profile. Etrasimod provides systemic and local effects on specific immune cell types and has the potential to treat multiple immune-mediated inflammatory diseases, including ulcerative colitis, Crohn’s disease, atopic dermatitis and alopecia areata. The drug is currently in phase 3 of clinical trials for the treatment of Atopic dermatitis; Ulcerative colitis.

Sphingosine 1 Phosphate Receptor Modulators: Therapeutic Assessment

This segment of the report provides insights about the different Sphingosine 1 Phosphate Receptor Modulators drugs segregated based on following parameters that define the scope of the report, such as:

Major Players working on Sphingosine 1 Phosphate Receptor Modulators

There are approx. 14+ key companies which are developing the Sphingosine 1 Phosphate Receptor Modulators. The companies which have their Sphingosine 1 Phosphate Receptor Modulators drug candidates in the most advanced stage, i.e. phase III include, Arena Pharmaceuticals.

Phases

This report covers around 14+ products under different phases of clinical development like

• Late-stage products (Phase III and
• Mid-stage products (Phase II and
• Early-stage products (Phase I/II and Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration

Sphingosine 1 Phosphate Receptor Modulators pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Infusion
• Intradermal
• Intramuscular
• Intranasal
• Intravaginal
• Oral
• Parenteral
• Subcutaneous
• Topical.

Molecule Type

Products have been categorized under various Molecule types such as

• Vaccines
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Sphingosine 1 Phosphate Receptor Modulators: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Sphingosine 1 Phosphate Receptor Modulators therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Sphingosine 1 Phosphate Receptor Modulators drugs.

Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence Sphingosine 1 Phosphate Receptor Modulators R&D. The therapies under development are focused on novel approaches for Sphingosine 1 Phosphate Receptor Modulators.

Sphingosine 1 Phosphate Receptor Modulators Report Insights

• Sphingosine 1 Phosphate Receptor Modulators Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Sphingosine 1 Phosphate Receptor Modulators Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions

Current Scenario and Emerging Therapies:

• How many companies are developing Sphingosine 1 Phosphate Receptor Modulators drugs?
• How many Sphingosine 1 Phosphate Receptor Modulators drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for Sphingosine 1 Phosphate Receptor Modulators?
• What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Sphingosine 1 Phosphate Receptor Modulators therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Sphingosine 1 Phosphate Receptor Modulators and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players

• Idorsia Pharmaceuticals
• Lpath
• Bristol-Myers Squibb
• Akaal Pharma
• Oppilan Pharma
• Boston Pharmaceuticals
• Trevena
• Corium International
• Janssen Pharmaceuticals
• Arena Pharmaceuticals
• Curadim Pharma
• Bridge Medicines
• Novartis
• Celgene Corporation
• Mitsubishi Tanabe Pharma Corporation
• LG Chem Life Sciences

Key Products

• Cenerimod
• Sonepcizumab
• BMS 986104
• AKP 11
• OPL 002
• BOS 173717
• TRV 045
• Fingolimod transdermal
• Ponesimod
• Etrasimod
• CP1050
• Siponimod
• Ozanimod
• Amiselimod
• LC51-0255

This product will be delivered within 2 business days.